// App-Quantinova.ai

DMT15 : Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Researchers

Presenter

  • Bruce A.C. Cree

Principal Investigators

  • Gavin Giovannoni

  • Ralf Gold

  • Robert J. Fox

  • Patrick Vermersch

  • Ralph H.B. Benedict

  • Amit Bar-Or

  • Nicolas Rouyrre

  • Daniela Piani-Meier

  • Shannon Ritter

  • Ajay Kilaru

  • Frank Dahlke

  • Goeril Karlsson

  • Ludwig Kappos

Medical Centers

  • Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RCNB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

  • Department for Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany

  • University Lille, INSERM U, CHU Lille, FHU Precise, Lille, France

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland, OH, USA

  • Novartis AG, Basel, Switzerland

  • Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

  • Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY

Locations

  • United States

  • Switzerland

  • Germany

  • France

  • United Kingdom

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Siponimod

Outcome

  • N/A

Study Design

  • Placebo Control

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved